巨噬細(xì)胞移動抑制因子(MIF)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Macrophage Migration Inhibitory Factor (MIF)
GIF; GLIF; MMIF; Glycosylation-Inhibiting Factor; L-dopachrome isomerase; L-dopachrome tautomerase; Phenylpyruvate tautomerase
- 編號USEA698Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3h
- 檢測范圍31.2-2,000pg/mL
- 靈敏度最小可檢測劑量小于等于11.9pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 1361 ¥ 1944 ¥ 8748 ¥ 16524 ¥ 136080
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測巨噬細(xì)胞移動抑制因子(MIF)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的巨噬細(xì)胞移動抑制因子(MIF)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 83-105 | 92 |
| EDTA plasma(n=5) | 79-91 | 86 |
| heparin plasma(n=5) | 80-90 | 85 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的巨噬細(xì)胞移動抑制因子(MIF)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中巨噬細(xì)胞移動抑制因子(MIF)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 82-90% | 89-103% | 93-104% | 97-104% |
| EDTA plasma(n=5) | 78-91% | 86-105% | 85-101% | 91-101% |
| heparin plasma(n=5) | 87-105% | 80-98% | 85-93% | 83-91% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將巨噬細(xì)胞移動抑制因子(MIF)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的巨噬細(xì)胞移動抑制因子(MIF)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的巨噬細(xì)胞移動抑制因子(MIF)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的巨噬細(xì)胞移動抑制因子(MIF)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPA698Mu01 | 巨噬細(xì)胞移動抑制因子(MIF)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA698Mu02 | 巨噬細(xì)胞移動抑制因子(MIF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA698Mu01 | 巨噬細(xì)胞移動抑制因子(MIF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA698Mu01 | 巨噬細(xì)胞移動抑制因子(MIF)多克隆抗體 | WB; IHC |
| UPAA698Mu02 | 巨噬細(xì)胞移動抑制因子(MIF)多克隆抗體 | WB; IHC; ICC; IP. |
| UFAA698Mu01 | 抗巨噬細(xì)胞移動抑制因子(MIF)多克隆抗體 | FCM |
| USEA698Mu | 巨噬細(xì)胞移動抑制因子(MIF)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA698Mu | 巨噬細(xì)胞移動抑制因子(MIF)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA698Mu | 巨噬細(xì)胞移動抑制因子(MIF)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Kidney International | Targeted reduction of advanced glycation improves renal function in obesity [PubMed: 21412218] |
| The Journal of Immunology | Macrophage Migration Inhibitory Factor Plays a Role in the Regulation of Microfold (M) Cell-Mediated Transport in the Gut [Jimmunol: 5673] |
| The Journal of Endocrinology | Involvement of exercise-induced macrophage migration inhibitory factor in the prevention of fatty liver disease [PubMed: PMC3757527] |
| The Journal of Immunology | Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice [PubMed: PMC3466372] |
| Diabetologia | Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes [Pubmed:24957662] |
| BioMed Research International | The Potential Role of Polymethyl Methacrylate as a New Packaging Material for the Implantable Medical Device in the Bladder [PubMed: 25705692] |
| Diabetologia | Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. [pubmed:28160092] |
| Life Sciences | Protective effect of chlorogenic acid on the inflammatory damage of pancreas and lung in mice with l-arginine-induced pancreatitis [pubmed:28919396] |
| Scientific Reports | Cytokine MIF Enhances Blood-Brain Barrier Permeability: Impact for Therapy in Ischemic Stroke [Pubmed:29335619] |
| Ocular?Immunology?and?Inflammation | Immune Response and Mechanisms of IFN-γ in Administration for Keratomycosis [Pubmed: 30307777] |
| International Journal of Immunopathology and Pharmacology | Effect of voluntary running on expression of myokines in brains of rats with depression [Pubmed: 30834799] |
| Biomarkers in Heart Failure and Associated Diseases | Biomarkers in Heart Failure and Associated Diseases [] |
| Science China-Life Sciences | Autophagy mediates the secretion of macrophage migration inhibitory factor from cardiomyocytes upon serum-starvation [Pubmed: 31209799] |
| Folia Morphologica | Beneficial effects of voluntary over forced exercise on skeletal muscle structure and myokines expression [Pubmed: 31802473] |
| Biomed Pharmacother | Deletion of macrophage migration inhibitory factor ameliorates inflammation in mice model severe acute pancreatitis [Pubmed: 32062385] |
| Sci Rep | Association between MIF gene promoter rs755622 and susceptibility to coronary artery disease and inflammatory cytokines in the Chinese Han population [33850223] |
| Commun Biol | Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes [Pubmed:35115654] |
